Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin to related CYP2D6*10 allele

Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism

Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes

Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide

ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan

CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes

Development of a column-switching LC-MS/MS method of tramadol and its metabolites in hair and application to a pharmacogenetic study

Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes

Development of a linear dual column HPLC-MS/MS method and clinical genetic evaluation for tramadol and its phase I and II metabolites in oral fluid

Inhibition of salivary secretion by tolterodine transdermal patch